Zepbound

Eli Lilly Stock After Q2 2026: Tirzepatide Is Becoming a Franchise, Not a Drug

Eli Lilly’s Q2 revenue jumped 48% to $23 billion as Mounjaro and Zepbound dominated growth. I examine obesity economics, pipeline depth, pricing, manufacturing and LLY valuation.

Mehr lesen